Adjuvant hormonal therapy following radical prostatectomy

Area of Science:

• Urology
• Oncology
• Surgical Oncology

Background:

• Adjuvant treatment following radical prostatectomy for advanced prostate cancer is a subject of ongoing clinical evaluation.
• Patients with extracapsular extension or lymph node positivity represent a high-risk group where treatment intensification is considered.

Purpose of the Study:

• To evaluate the efficacy of adjuvant treatment in improving oncological outcomes after radical prostatectomy in patients with specific adverse pathological features.
• To determine if adjuvant therapy impacts time to progression and cause-specific survival in men with pT3 pN0 or node-positive prostate cancer.

Main Methods:

• Retrospective analysis of 293 patients who underwent radical prostatectomy.
• Comparison of outcomes between 86 patients who received adjuvant treatment and those who did not.
• Analysis focused on time to progression and cause-specific survival, with stage-correlated subgroup analyses.

Main Results:

• Initial analysis showed better outcomes in the control group, attributed to pathological stage imbalance.
• Stage-correlated analysis revealed no significant benefit in time to progression or survival for adjuvant-treated patients with pT3 pN0 tumors.
• Adjuvant therapy demonstrated no impact on time to progression or survival in patients with positive pelvic lymph nodes.

Conclusions:

• Current evidence does not support routine adjuvant treatment for all patients with extracapsular or node-positive prostate cancer.
• Further research may be needed to identify specific subgroups who could benefit from adjuvant therapies.
• The study suggests a need for careful patient selection and individualized treatment strategies.